For the quarter ending 2026-03-31, HROW made $44,203K in revenue. -$27,602K in net income. Net profit margin of -62.44%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 44,203 | 89,092 | 71,638 | 63,742 |
| Cost of sales | 17,158 | 18,468 | 17,712 | 16,230 |
| Gross profit | 27,045 | 70,624 | 53,926 | 47,512 |
| Selling, general and administrative | 43,230 | 43,310 | 35,856 | 33,235 |
| Research and development | 5,895 | 11,723 | 3,323 | 2,868 |
| Total operating expenses | 49,125 | 55,033 | 39,179 | 36,103 |
| Loss from operations | -22,080 | 15,591 | 14,747 | 11,409 |
| Gain on extinguishment of debt | - | 28* | -7,750 | - |
| Other income (expense), net | - | -35* | 61 | -6 |
| Interest expense, net | 5,497 | 5,186 | 6,038 | 6,408 |
| Investment loss from eton pharmaceuticals | - | - | - | 0 |
| Total other expense, net | - | -5,194 | -13,727 | -6,414 |
| Loss before income taxes | -27,577 | 10,397* | 1,020 | 4,995 |
| Income tax expense | 25 | 3,771* | - | 0 |
| Net gain | -27,602 | 6,626 | 1,020 | 4,995 |
| Basic EPS | -0.74 | 0.178 | 0.03 | 0.14 |
| Diluted EPS | -0.74 | 0.198 | 0.03 | 0.13 |
| Basic Average Shares | 37,231,321 | 37,279,646 | 37,145,440 | 36,790,306 |
| Diluted Average Shares | 37,231,321 | 33,486,532 | 38,875,005 | 38,853,855 |
HARROW, INC. (HROW)
HARROW, INC. (HROW)